The antibody drug conjugate, belantamab-mafodotin, in the treatment of multiple myeloma: A comprehensive review

Last Updated: Wednesday, January 22, 2025

Multiple myeloma (MM) remains largely incurable, with relapses due to therapy resistance. This review highlights belantamab mafodotin, the first antibody-drug conjugate targeting BCMA, which is predominantly expressed in malignant plasma cells. By disrupting microtubules and signaling pathways, it shows promise in treating relapsed/refractory MM, as evidenced by pre-clinical and clinical DREAMM studies.

Blood and Lymphatic Cancer: Targets and Therapy

JCO Precision Oncology

Expanding the therapeutic reach of chimeric antigen receptor T-cells and bispecific T-cell engagers across solid tumors

Open Forum Infectious Diseases

Outcomes and risk factors for influenza and respiratory syncytial virus lower respiratory tract infections and mortality in patients with lymphoma or multiple myeloma: A 7-year retrospective cohort study

Cancer Reports

Efficacy and safety of quadruplet therapy in newly diagnosed transplant-eligible multiple myeloma: A systematic review and meta-analysis

Clinical Lymphoma, Myeloma & Leukemia

Expert perspectives on current challenges and emerging approaches for multiple myeloma: Narrative review of an inaugural bridging the gaps in leukemia, lymphoma, and multiple myeloma

Cancer Medicine

Application of GPRC5D targeting therapy in relapsed refractory multiple myeloma

The Lancet Haematology

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): A multicentre, open-label, phase 1-2 study

Mediterranean Journal of Hematology and Infectious Diseases

How first-line therapy is changing in non-transplant eligible multiple myeloma patients

Cancer Medicine

Treatment of multiple myeloma in patients refractory to daratumumab/anti-CD38 monoclonal antibodies: A systematic review

Iranian Journal of Medical Sciences

Advancing multiple myeloma immunotherapy: A review of chimeric antigen receptor T-cell and bispecific T-cell engagers cell therapies in revolutionizing treatment

European Journal of Haematology

Completion of distress screening and correlates of distress score in patients with multiple myeloma at initial evaluation at a transplant center

Multiple Myeloma Resource Center

The antibody drug conjugate, belantamab-mafodotin, in the treatment of multiple myeloma: A comprehensive review

JCO Precision Oncology

Expanding the therapeutic reach of chimeric antigen receptor T-cells and bispecific T-cell engagers across solid tumors

Open Forum Infectious Diseases

Outcomes and risk factors for influenza and respiratory syncytial virus lower respiratory tract infections and mortality in patients with lymphoma or multiple myeloma: A 7-year retrospective cohort study

Cancer Reports

Efficacy and safety of quadruplet therapy in newly diagnosed transplant-eligible multiple myeloma: A systematic review and meta-analysis

Clinical Lymphoma, Myeloma & Leukemia

Expert perspectives on current challenges and emerging approaches for multiple myeloma: Narrative review of an inaugural bridging the gaps in leukemia, lymphoma, and multiple myeloma

Cancer Medicine

Application of GPRC5D targeting therapy in relapsed refractory multiple myeloma

The Lancet Haematology

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): A multicentre, open-label, phase 1-2 study

Mediterranean Journal of Hematology and Infectious Diseases

How first-line therapy is changing in non-transplant eligible multiple myeloma patients

Cancer Medicine

Treatment of multiple myeloma in patients refractory to daratumumab/anti-CD38 monoclonal antibodies: A systematic review

Iranian Journal of Medical Sciences

Advancing multiple myeloma immunotherapy: A review of chimeric antigen receptor T-cell and bispecific T-cell engagers cell therapies in revolutionizing treatment

European Journal of Haematology

Completion of distress screening and correlates of distress score in patients with multiple myeloma at initial evaluation at a transplant center

Treatment of Intermediate Risk Smoldering Myeloma

Patient Newly Diagnosed With MM and Ineligible for SCT With Relapse on Anti-CD38 and Lenalidomide-Based Therapy

Single Solitary Plasmacytoma to Active Myeloma